This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend)
This information is for research and educational use only.
Quick Reference
What is Tesamorelin 5mg + Ipamorelin 5mg?
Research overview based on the cited scientific literature.
• Goal: Support pulsatile GH release through dual GHRH + ghrelin pathway stimulation[1][2].
• Storage: Lyophilized refrigerated 2–8 °C; reconstituted use immediately or within 24–48 hours.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; may be kept at ≤25 °C (77 °F) up to 3 months after dispensing[5].
• Reconstituted: Inject immediately after reconstitution; if stored, refrigerate and use within 24–48 hours; do not freeze[5].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Tesamorelin 5mg + Ipamorelin 5mg studied?
Tesamorelin is a synthetic 44aminoacid GHRH analog that stimulates pituitary GH release[3]. Ipamorelin is a pentapeptide ghrelin mimetic that acts on the GHSR1a receptor, selectively stimulating GH secretion without significantly affecting cortisol, prolactin, or ACTH[4][7]. Combined GHRH + GHRP/ghrelinmimetic administration produces synergistic, amplified GH pulses compared to either agent alone[1][2]. Human pharmacokinetic studies show ipamorelin achieves peak GH release approximately 40 minutes postdose[8].
What does the research report about Tesamorelin 5mg + Ipamorelin 5mg?
Observations from preclinical and clinical literature.
• Enhanced pulsatile GH secretion through dualpathway stimulation[1][2].
• Tesamorelin (2 mg/day) demonstrated reductions in trunk fat and visceral adipose tissue in HIVassociated lipodystrophy trials[3][9].
• Ipamorelin shows high GH selectivity with minimal impact on cortisol or other hormones[4][7].
• Common adverse events with tesamorelin include injectionsite reactions (erythema, pruritus), arthralgia, and peripheral edema[5][9].
• Ipamorelin is generally well tolerated; transient flushing or headache may occur[7].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Tesamorelin 5mg + Ipamorelin 5mg?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
